Delcath Systems
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell DCTH and other ETFs, options, and stocks.About DCTH
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO.
CEOGerard J. Michel
CEOGerard J. Michel
Employees96
Employees96
HeadquartersQueensbury, New York
HeadquartersQueensbury, New York
Founded1988
Founded1988
Employees96
Employees96
DCTH Key Statistics
Market cap304.76M
Market cap304.76M
Price-Earnings ratio1.00K
Price-Earnings ratio1.00K
Dividend yield—
Dividend yield—
Average volume1.27M
Average volume1.27M
High today$8.70
High today$8.70
Low today$8.33
Low today$8.33
Open price$8.65
Open price$8.65
Volume1.11M
Volume1.11M
52 Week high$18.23
52 Week high$18.23
52 Week low$8.33
52 Week low$8.33
Stock Snapshot
Delcath Systems(DCTH) stock is priced at $8.42, giving the company a market capitalization of 304.76M. It carries a P/E multiple of 1004.65.
On 2025-11-08, Delcath Systems(DCTH) stock traded between a low of $8.33 and a high of $8.70. Shares are currently priced at $8.42, which is +1.1% above the low and -3.2% below the high.
Delcath Systems(DCTH) shares are trading with a volume of 1.11M, against a daily average of 1.27M.
During the past year, Delcath Systems(DCTH) stock moved between $8.33 at its lowest and $18.23 at its peak.
During the past year, Delcath Systems(DCTH) stock moved between $8.33 at its lowest and $18.23 at its peak.
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own DCTH. This list is generated using Robinhood data, and it’s not a recommendation.